



## ASX ANNOUNCEMENT

14 March 2024

### Resignation of Chairman

**Melbourne, Australia – Opyl Limited (ASX:OPL)** today announced that non-executive Chair Mr Mark Ziirsen has tendered his resignation from the Board, effective 30 April 2024. The company will commence a search for a new Chair and expects to make an appointment as soon as possible to enable an appropriate transition process.

Mr Ziirsen joined as a non-executive director in September 2020, serving as Chair since August 2022, as well as having served on and chaired the Audit and Risk Committee and the Remuneration Committee.

Mr Ziirsen has advised that, being up for re-election at the Company's next Annual General Meeting (AGM), he has decided that he would not be able to commit to a further three-year term and felt that with the Company in an excellent position the time was right to transition to a new chair who could lead the Company through and beyond the next AGM.

Mr Ziirsen's decisions comes following a year of significant transition having led the business as its Executive Chair during which time he was instrumental in delivering:

- A re-set of the Company's executive senior leadership team with the appointment of Saurabh Jain as interim CEO and Dr Hugo Stephenson as Head of Opin
- A refresh of the board with the appointment of Mark Simari and Antanas Guoga to the Board as Non-Executive Directors
- Significant milestones for Opyl's AI platform, TrialKey, including completion of core technology development, expansion of data set and features, improvements to accuracy and establishing go-to-market strategy, and officially launched to the public
- Strengthened Balance Sheet, raising a total of \$2.5m (before costs), providing a strong platform for growth

Mr Mark Simari, non-executive director said: *'On behalf of Opyl Limited and the Board, I would like to thank Mark for his outstanding contribution and invaluable support of the business over the past three and half years. He leaves the Company strongly positioned to realise it strategy. He has been a pleasure to work with and a valuable partner to both myself and the organisation during his time as Chair.'*

The Board has authorised this announcement for release to the ASX.

**-ENDS-**



**For investor enquiries:**

Saurabh Jain  
Interim CEO  
Phone: +61 400 748 587  
Email: [saurabh@opyl.ai](mailto:saurabh@opyl.ai)

**For general enquiries:**

Email: [info@opyl.ai](mailto:info@opyl.ai)  
Website: [www.opyl.ai](http://www.opyl.ai)

**About Opyl Limited**

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials and predicting outcomes. Our platforms provide targeted insights that make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money. Our key offering for biopharma, medtech, government and healthcare organisations are Opin.ai (clinical trial recruitment solutions) and Trial Key (clinical trial predictive analytics and protocol design).